GDTC
CytoMed Therapeutics Limited
Price Chart
Latest Quote
$0.89
-0.04 (-3.91%)
Current Price
| Previous Close | $0.93 |
| Open | $0.89 |
| Day High | $0.89 |
| Day Low | $0.89 |
| Volume | 332 |
Stock Information
Note: Financial values converted from SGD to USD
| Shares Outstanding | 11.93M |
| Total Debt | $355K |
| Cash Equivalents | $1.14M |
| Revenue | $616K |
| Net Income | $-2.74M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.62M |
| EPS (TTM) | $-0.23 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.48M |
| Sales | $616K |
| Income | $-2.74M |
| Book/sh | $0.33 |
| Cash/sh | $0.12 |
| Employees | 42 |
Financial Ratios
| Quick Ratio | 1.51 |
| Current Ratio | 2.64 |
| Debt/Eq | 8.41 |
Returns & Margins
| ROA | -32.52% |
| ROE | -56.17% |
| Gross Margin | 85.89% |
| Operating Margin | -476.09% |
Ownership
| Insider Ownership | 70.49% |
| Institutional Ownership | 0.14% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.93 |
| P/S | 13.46 |
| P/B | 2.73 |
Analyst Data
| Recommendation | none |
| Target Price | $4.16 |
Technical Indicators
| SMA20 | $0.90 |
| SMA50 | $0.90 |
| SMA200 | $0.98 |
| RSI | 38.64 |
| ATR | 0.0955 |
| Shares Float | 3.52M |
| Short Float | 0.48% |
| Short Ratio | 1.26 |
| Volatility | 0.07 |
| Rel Volume | 0.02 |
Performance History
| Week | +2.06% |
| Month | -3.78% |
| Quarter | -2.20% |
| 6 Months | -1.11% |
| YTD | -35.97% |
| Year | -62.76% |
| 3 Years | -75.21% |
| 10 Years | -77.75% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $0.89 | 332 |
| 2026-10-26 | $0.93 | 12,500 |
| 2026-10-23 | $0.92 | 4,300 |
| 2026-10-22 | $0.92 | 5,900 |
| 2026-10-21 | $0.92 | 5,000 |
| 2026-10-20 | $0.87 | 8,300 |
| 2026-10-19 | $0.85 | 15,000 |
| 2026-10-16 | $0.88 | 7,300 |
| 2026-10-15 | $0.87 | 9,500 |
| 2026-10-14 | $0.86 | 10,600 |
| 2026-10-13 | $0.87 | 24,000 |
| 2026-10-12 | $0.81 | 54,800 |
| 2026-10-09 | $0.89 | 11,800 |
| 2026-10-08 | $0.94 | 23,200 |
| 2026-10-07 | $0.98 | 15,200 |
| 2026-10-06 | $0.93 | 18,600 |
| 2026-10-05 | $1.01 | 63,800 |
| 2026-10-02 | $0.92 | 33,700 |
| 2026-10-01 | $0.90 | 6,400 |
| 2026-09-30 | $0.84 | 13,000 |
| 2026-09-29 | $0.89 | 25,400 |
| 2026-09-28 | $0.93 | 6,500 |
About CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
đ° Latest News
No news articles available at the moment. Check back later for updates on GDTC.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $53,169 | $13,388 | $0 | $0 |
| Cost Of Revenue | $53,169 | $13,388 | $0 | $0 |
| Total Revenue | $253,667 | $54,349 | $0 | $0 |
| Operating Revenue | $253,667 | $54,349 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $16,348 | $15,885 | $40,102 | $97,885 |
| Total Expenses | $3,570,614 | $2,502,388 | $3,005,064 | $1,451,815 |
| Rent Expense Supplemental | $4,119 | $2,514 | $1,332 | $1,721 |
| Other Income Expense | $111,316 | $243,441 | $-409,847 | $-899,419 |
| Other Non Operating Income Expenses | $6,587 | - | $-77,225 | $-852,744 |
| Net Non Operating Interest Income Expense | $80,539 | $232,530 | $183,327 | $-96,246 |
| Interest Expense Non Operating | $16,348 | $15,885 | $40,102 | $97,885 |
| Operating Expense | $3,517,445 | $2,489,000 | $3,005,064 | $1,451,815 |
| Other Operating Expenses | $157,565 | $-96,273 | $671,183 | $-142,401 |
| Selling And Marketing Expense | $42,520 | $18,597 | $26,046 | $0 |
| General And Administrative Expense | $1,398,544 | $971,159 | $978,136 | $310,537 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,112,674 | $-1,968,031 | $-3,231,880 | $-2,448,572 |
| Net Interest Income | $80,539 | $232,530 | $183,327 | $-96,246 |
| Interest Income | $96,887 | $248,415 | $223,429 | $1,640 |
| Normalized Income | $-3,222,402 | $-2,200,708 | $-2,976,053 | $-2,431,604 |
| Net Income From Continuing And Discontinued Operation | $-3,112,674 | $-1,968,031 | $-3,231,880 | $-2,448,572 |
| Net Income Common Stockholders | $-3,112,674 | $-1,968,031 | $-3,231,880 | $-2,448,572 |
| Net Income | $-3,112,674 | $-1,968,031 | $-3,231,880 | $-2,448,572 |
| Net Income Including Noncontrolling Interests | $-3,125,092 | $-1,972,068 | $-3,232,094 | $-2,448,762 |
| Net Income Continuous Operations | $-3,125,092 | $-1,972,068 | $-3,232,094 | $-2,448,762 |
| Pretax Income | $-3,125,092 | $-1,972,068 | $-3,231,584 | $-2,447,479 |
| Special Income Charges | $223,436 | $0 | $0 | $219 |
| Earnings From Equity Interest | $-4,998 | $10,764 | $-24,396 | $-26,233 |
| Interest Income Non Operating | $96,887 | $248,415 | $223,429 | $1,640 |
| Operating Income | $-3,316,946 | $-2,448,039 | $-3,005,064 | $-1,451,815 |
| Depreciation Amortization Depletion Income Statement | $177,352 | $95,715 | $81,368 | $87,384 |
| Depreciation And Amortization In Income Statement | $177,352 | $95,715 | $81,368 | $87,384 |
| Amortization Of Intangibles Income Statement | $23,381 | $9,819 | $1,710 | $1,955 |
| Depreciation Income Statement | $153,971 | $85,895 | $79,658 | $85,429 |
| Gross Profit | $200,498 | $40,961 | $0 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.27 | - | $-0.30 | $-0.22 |
| Basic EPS | $-0.27 | - | $-0.30 | $-0.22 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-52,398 | $-3,475 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-2,904,436 | $-1,926,610 | $-2,585,202 | $-2,021,933 |
| Total Unusual Items | $109,727 | $232,677 | $-308,226 | $-20,443 |
| Total Unusual Items Excluding Goodwill | $109,727 | $232,677 | $-308,226 | $-20,443 |
| Reconciled Depreciation | $314,034 | $262,250 | $298,054 | $307,218 |
| EBITDA (Bullshit earnings) | $-2,794,709 | $-1,693,933 | $-2,893,428 | $-2,042,376 |
| EBIT | $-3,108,743 | $-1,956,184 | $-3,191,482 | $-2,349,594 |
| Diluted Average Shares | $9,108,004 | - | $8,312,814 | $8,554,820 |
| Basic Average Shares | $9,108,004 | - | $8,312,814 | $8,554,820 |
| Diluted NI Availto Com Stockholders | $-3,112,674 | $-1,968,031 | $-3,231,880 | $-2,448,572 |
| Minority Interests | $12,417 | $4,037 | $214 | $190 |
| Tax Provision | $0 | $0 | $511 | $1,282 |
| Gain On Sale Of Business | $230,089 | $0 | $0 | - |
| Impairment Of Capital Assets | $6,653 | $0 | $0 | - |
| Gain On Sale Of Security | $-113,709 | $232,677 | $-308,226 | $-20,662 |
| Other Taxes | $7,407 | $6,578 | $5,209 | $5,509 |
| Amortization | $23,381 | $9,819 | $1,710 | $1,955 |
| Research And Development | $1,734,057 | $1,493,223 | $1,243,123 | $1,190,786 |
| Selling General And Administration | $1,441,064 | $989,757 | $1,004,181 | $310,537 |
| Other Gand A | $365,706 | $410,544 | $400,525 | $144,084 |
| Insurance And Claims | $0 | $73,794 | $221,144 | $0 |
| Rent And Landing Fees | $4,119 | $2,514 | $1,332 | $1,721 |
| Salaries And Wages | $1,028,719 | $484,307 | $355,135 | $164,731 |
| Gain On Sale Of Ppe | - | $0 | $0 | $219 |
Fetched: 2026-10-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,020,020 | $6,938,582 | $8,783,849 | $444,304 |
| Total Assets | $6,244,147 | $7,872,871 | $9,672,323 | $4,087,503 |
| Total Non Current Assets | $3,379,740 | $3,180,386 | $1,776,866 | $2,137,330 |
| Non Current Accounts Receivable | $381,049 | $390,995 | - | - |
| Investmentin Financial Assets | $14,240 | $0 | - | - |
| Goodwill And Other Intangible Assets | $97,666 | $72,764 | $9,707 | $14,708 |
| Other Intangible Assets | $97,388 | $72,486 | $9,429 | $14,431 |
| Current Assets | $2,864,407 | $4,692,485 | $7,895,456 | $1,950,173 |
| Prepaid Assets | $1,122,492 | $710,928 | $701,300 | $669,822 |
| Receivables | $103,265 | $94,783 | $160,111 | $45,029 |
| Other Receivables | $17,054 | $49,362 | $10,407 | $45,029 |
| Taxes Receivable | $4,102 | $2,262 | $3,683 | - |
| Accrued Interest Receivable | $892 | $28,473 | $146,021 | - |
| Accounts Receivable | $81,217 | $14,687 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $1,638,650 | $3,886,773 | $7,034,045 | $1,235,322 |
| Cash And Cash Equivalents | $1,638,650 | $3,886,773 | $7,034,045 | $1,235,322 |
| Cash Financial | $1,638,650 | $3,886,773 | $7,034,045 | $1,235,322 |
| Debt | ||||
| Total Debt | $377,358 | $362,256 | $350,348 | $3,299,417 |
| Long Term Debt And Capital Lease Obligation | $330,091 | $326,354 | $318,873 | $371,864 |
| Long Term Debt | $288,285 | $308,346 | $318,873 | $366,618 |
| Current Debt And Capital Lease Obligation | $47,267 | $35,903 | $31,475 | $2,927,553 |
| Current Debt | $31,942 | $29,442 | $26,530 | $2,921,524 |
| Other Current Borrowings | $31,942 | $29,442 | $26,530 | $2,921,524 |
| Net Debt | - | - | - | $2,052,819 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $884,653 | $800,726 | $879,515 | $3,629,024 |
| Total Non Current Liabilities Net Minority Interest | $330,091 | $326,354 | $318,873 | $371,864 |
| Current Liabilities | $554,562 | $474,372 | $560,642 | $3,257,160 |
| Other Current Liabilities | $19,600 | $9,341 | $114,650 | - |
| Current Deferred Liabilities | $142,953 | $85,354 | $6,569 | $7,119 |
| Payables And Accrued Expenses | $344,742 | $343,774 | $407,948 | $322,488 |
| Payables | $147,385 | $59,373 | $58,685 | $138,009 |
| Other Payable | $47,762 | $29,162 | $39,434 | $124,332 |
| Total Tax Payable | $2,076 | $0 | $0 | $1,248 |
| Accounts Payable | $97,547 | $30,211 | $19,251 | $11,439 |
| Equity | ||||
| Common Stock Equity | $5,117,686 | $7,011,346 | $8,793,555 | $459,012 |
| Total Equity Gross Minority Interest | $5,359,494 | $7,072,145 | $8,792,808 | $458,479 |
| Stockholders Equity | $5,117,686 | $7,011,346 | $8,793,555 | $459,012 |
| Other Equity Interest | $86,977 | - | $57,812 | - |
| Gains Losses Not Affecting Retained Earnings | $473,028 | $15,816 | $-170,006 | $-99,691 |
| Other Equity Adjustments | $411,820 | $57,853 | - | - |
| Retained Earnings | $-14,723,756 | $-11,611,081 | $-9,643,051 | $-6,411,171 |
| Long Term Equity Investment | $0 | $172,781 | $152,545 | $187,227 |
| Other | ||||
| Ordinary Shares Number | $9,249,708 | $9,024,155 | $9,015,810 | $8,554,820 |
| Share Issued | $9,249,708 | $9,024,155 | $9,015,810 | $8,554,820 |
| Tangible Book Value | $5,020,020 | $6,938,582 | $8,783,849 | $444,304 |
| Invested Capital | $5,437,913 | $7,349,135 | $9,138,958 | $3,747,154 |
| Working Capital | $2,309,844 | $4,218,113 | $7,334,815 | $-1,306,987 |
| Capital Lease Obligations | $57,131 | $24,468 | $4,945 | $11,276 |
| Total Capitalization | $5,405,971 | $7,319,693 | $9,112,429 | $825,630 |
| Minority Interest | $241,807 | $60,799 | $-748 | $-533 |
| Foreign Currency Translation Adjustments | $61,209 | $-42,037 | $-170,006 | $-99,691 |
| Capital Stock | $19,281,437 | $18,606,612 | $18,548,799 | $6,969,874 |
| Common Stock | $19,281,437 | $18,606,612 | $18,548,799 | $6,969,874 |
| Long Term Capital Lease Obligation | $41,806 | $18,008 | $0 | $5,246 |
| Current Deferred Revenue | $142,953 | $85,354 | $6,569 | $7,119 |
| Current Capital Lease Obligation | $15,325 | $6,461 | $4,945 | $6,029 |
| Current Accrued Expenses | $197,358 | $284,402 | $349,263 | $184,479 |
| Investments And Advances | $14,240 | $172,781 | $152,545 | $187,227 |
| Available For Sale Securities | $14,240 | - | - | - |
| Investmentsin Associatesat Cost | $0 | $172,781 | $152,545 | $187,227 |
| Goodwill | $278 | $278 | $278 | $278 |
| Net PPE | $2,886,785 | $2,543,847 | $1,614,615 | $1,935,394 |
| Accumulated Depreciation | $-1,726,130 | $-1,381,678 | $-1,067,176 | $-823,219 |
| Gross PPE | $4,612,915 | $3,925,525 | $2,681,791 | $2,758,613 |
| Other Properties | $2,127,761 | $1,556,653 | $1,303,243 | $1,330,688 |
| Machinery Furniture Equipment | $400,938 | $350,178 | $258,216 | $262,751 |
| Buildings And Improvements | $1,605,939 | $1,558,852 | $829,271 | $856,378 |
| Land And Improvements | $478,277 | $459,842 | $291,061 | $308,797 |
| Properties | $0 | $0 | $0 | $0 |
| Dueto Related Parties Current | - | - | $0 | $989 |
| Duefrom Related Parties Current | - | - | - | $0 |
Fetched: 2026-10-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,441,219 | $-3,287,768 | $-2,806,943 | $-1,464,043 |
| Operating Activities | ||||
| Operating Cash Flow | $-2,891,376 | $-2,119,135 | $-2,761,357 | $-1,093,541 |
| Cash Flow From Continuing Operating Activities | $-2,891,376 | $-2,119,135 | $-2,761,357 | $-1,093,541 |
| Operating Gains Losses | $-169,630 | $-131,445 | $197,459 | $9,078 |
| Investing Activities | ||||
| Capital Expenditure | $-549,843 | $-1,168,633 | $-45,586 | $-370,503 |
| Investing Cash Flow | $726,689 | $880,943 | $-2,135,463 | $-370,119 |
| Cash Flow From Continuing Investing Activities | $726,689 | $880,943 | $-2,135,463 | $-370,119 |
| Net Other Investing Changes | $-16,050 | $-390,995 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $221,376 | $0 | $8,841,971 | $956,099 |
| Financing Cash Flow | $163,160 | $-50,745 | $8,539,232 | $757,525 |
| Cash Flow From Continuing Financing Activities | $163,160 | $-50,745 | $8,539,232 | $757,525 |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $221,376 | $0 | $8,841,971 | $956,099 |
| Common Stock Issuance | $221,376 | $0 | $8,841,971 | $956,099 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-41,868 | $-34,860 | $-266,209 | $-335,285 |
| End Cash Position | $1,638,650 | $3,673,040 | $4,867,247 | $1,235,322 |
| Beginning Cash Position | $3,673,040 | $4,867,247 | $1,235,322 | $1,964,957 |
| Effect Of Exchange Rate Changes | $-32,864 | $94,730 | $-10,487 | $-23,500 |
| Changes In Cash | $-2,001,526 | $-1,288,937 | $3,642,412 | $-706,135 |
| Interest Paid Cff | $-16,348 | $-15,885 | $-36,529 | $-97,885 |
| Net Issuance Payments Of Debt | $-41,868 | $-34,860 | $-266,209 | $-100,688 |
| Net Long Term Debt Issuance | $-41,868 | $-34,860 | $-266,209 | $-100,688 |
| Long Term Debt Payments | $-41,868 | $-34,860 | $-266,209 | $-335,285 |
| Interest Received Cfi | $126,825 | $364,068 | $76,921 | $0 |
| Net Investment Purchase And Sale | $213,733 | $1,953,065 | $-2,166,798 | $0 |
| Sale Of Investment | $213,733 | $1,953,065 | - | - |
| Net Business Purchase And Sale | $952,025 | $123,437 | $0 | $0 |
| Sale Of Business | $952,025 | $123,437 | $0 | - |
| Net Intangibles Purchase And Sale | $-51,051 | $-73,672 | $0 | $0 |
| Purchase Of Intangibles | $-51,051 | $-73,672 | $0 | $0 |
| Net PPE Purchase And Sale | $-498,792 | $-1,094,961 | $-45,586 | $-370,119 |
| Purchase Of PPE | $-498,792 | $-1,094,961 | $-45,586 | $-370,503 |
| Taxes Refund Paid | $0 | $0 | $-1,716 | $0 |
| Interest Received Cfo | $0 | $1,894 | $487 | $1,640 |
| Change In Working Capital | $-379,660 | $-47,237 | $82,045 | $85,942 |
| Change In Other Working Capital | $56,343 | $79,987 | $1,526 | $-7,811 |
| Change In Payables And Accrued Expense | $-133 | $-65,375 | $84,631 | $207,273 |
| Change In Payable | $-133 | $-65,375 | $84,631 | $207,273 |
| Change In Receivables | $-435,871 | $-61,848 | $-4,112 | $-113,521 |
| Other Non Cash Items | $-80,539 | $-232,530 | $-183,327 | $96,246 |
| Stock Based Compensation | $542,857 | $0 | $0 | - |
| Unrealized Gain Loss On Investment Securities | $0 | $0 | $77,225 | $852,744 |
| Asset Impairment Charge | $6,653 | $0 | $0 | $1,071 |
| Depreciation Amortization Depletion | $314,034 | $262,250 | $298,054 | $307,218 |
| Depreciation And Amortization | $314,034 | $262,250 | $298,054 | $307,218 |
| Amortization Cash Flow | $23,884 | $10,321 | $5,002 | $10,322 |
| Amortization Of Intangibles | $23,884 | $10,321 | $5,002 | $10,322 |
| Depreciation | $290,151 | $251,929 | $293,052 | $296,895 |
| Earnings Losses From Equity Investments | $4,998 | $-10,764 | $24,396 | $26,233 |
| Gain Loss On Investment Securities | $10,259 | $-108,143 | $175,044 | - |
| Net Foreign Currency Exchange Gain Loss | $45,203 | $-12,538 | $-1,982 | $-16,936 |
| Gain Loss On Sale Of Business | $-230,089 | $0 | $0 | - |
| Net Income From Continuing Operations | $-3,125,092 | $-1,972,068 | $-3,231,584 | $-2,447,479 |
| Issuance Of Debt | - | $0 | $0 | $234,597 |
| Long Term Debt Issuance | - | $0 | $0 | $234,597 |
| Sale Of PPE | - | $0 | $0 | $383 |
| Gain Loss On Sale Of PPE | - | $0 | $0 | $-219 |
| Net Short Term Debt Issuance | - | - | $-234,597 | $-39,099 |
| Short Term Debt Payments | - | - | $-234,597 | $-273,696 |
| Short Term Debt Issuance | - | - | $0 | $234,597 |
| Purchase Of Investment | - | - | $-2,166,798 | $0 |
| Purchase Of Business | - | - | $0 | $0 |
Fetched: 2026-10-26